NASDAQ$REGN
Regeneron Pharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Regeneron's financial performance was strong in Q2 2023, driven by diversified revenue streams and pipeline advancements.
Regeneron reported an 11% increase in revenue to $3.16 billion for the second quarter of 2023. GAAP diluted EPS was $8.50, and non-GAAP diluted EPS was $10.24. The company progressed its pipeline, including aflibercept 8 mg, and saw a 33% increase in Dupixent global net sales.
- Total revenues increased by 11% to $3.16 billion compared to Q2 2022.
- Dupixent global net sales (recorded by Sanofi) increased by 33% to $2.79 billion compared to Q2 2022.
- EYLEA U.S. net sales were $1.50 billion.
- GAAP diluted EPS was $8.50, and non-GAAP diluted EPS was $10.24.
Headline financials
Revenue & EPS history
Regeneron · Revenue · Quarterly
$3.16B
Revenue by segment
Regeneron · $3.41B total across 6 segments · Q1 2023
- Net product sales$1.67B+1.8%48.9%
- EYLEA U.S.$1.43B—42.1%
- Other revenue$116M+23.4%3.4%
- Libtayo U.S.$110M—3.2%
- Libtayo ROW$67M—2.0%
- Evkeeza U.S.$15M—0.4%
Forward guidance
Regeneron updated its full year 2023 financial guidance.
Tailwinds
- GAAP R&D guidance updated to $4.315–$4.455 billion.
- Non-GAAP R&D guidance updated to $3.825–$3.925 billion.
- GAAP SG&A guidance updated to $2.540–$2.680 billion.
- Non-GAAP SG&A guidance updated to $2.180–$2.280 billion.
- GAAP effective tax rate updated to 8%-9%.
Headwinds
- No specific negative aspects were provided, the guidance update mainly involved adjustments to projected figures without highlighting explicit concerns or risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.5%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+3.1%
Avg return
30 days after
54%
35 / 65 earnings
Positive
+11.7%
Q2 2012
Best reaction
-8.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | -3.1% | -16.0% | |
| Q4 2025 | -0.5% | +3.4% | +4.3% | |
| Q3 2025 | +11.1% | +11.4% | +34.1% | |
| Q2 2025 | +2.5% | +1.8% | +6.5% | |
| Q1 2025 | -6.9% | -0.9% | -0.9% | |
| Q4 2024 | +4.5% | +6.5% | +4.7% | |
| Q3 2024 | -8.6% | -10.1% | -18.7% | |
| Q2 2024 | +0.3% | -1.2% | +9.8% | |
| Q1 2024 | +5.9% | +7.4% | +8.5% | |
| Q4 2023 | -2.2% | -2.0% | +2.6% | |
| Q3 2023 | +3.2% | +5.0% | +3.0% | |
| Q2 2023 | +4.7% | +6.6% | +13.6% | |
| Q1 2023 | -5.1% | -6.0% | -7.9% | |
| Q4 2022 | +3.9% | -0.2% | +3.7% | |
| Q3 2022 | -0.0% | +1.5% | +3.5% | |
| Q2 2022 | +7.0% | +9.7% | +1.0% | |
| Q1 2022 | -3.2% | -9.2% | -4.6% | |
| Q4 2021 | +0.3% | -0.1% | -0.0% | |
| Q3 2021 | -6.2% | -5.5% | -2.6% | |
| Q2 2021 | +5.1% | +5.9% | +17.0% | |
| Q1 2021 | +3.0% | +3.9% | +6.1% | |
| Q4 2020 | -0.8% | -1.5% | -7.5% | |
| Q3 2020 | -1.6% | -4.8% | -16.1% | |
| Q2 2020 | -4.2% | -6.2% | -10.5% | |
| Q1 2020 | +2.2% | +4.0% | +10.5% | |
| Q4 2019 | +2.6% | +6.6% | +32.9% | |
| Q3 2019 | +4.3% | +9.9% | +18.4% | |
| Q2 2019 | +0.9% | +1.8% | -3.4% | |
| Q1 2019 | -4.4% | -9.1% | -13.0% | |
| Q4 2018 | -3.5% | -3.0% | -4.4% | |
| Q3 2018 | +2.6% | +0.5% | +7.5% | |
| Q2 2018 | +6.4% | +5.5% | +9.6% | |
| Q1 2018 | -1.7% | -3.5% | +3.6% | |
| Q4 2017 | +0.5% | -3.0% | +2.1% | |
| Q3 2017 | +0.5% | -2.7% | -5.8% | |
| Q2 2017 | -1.7% | -1.5% | +5.7% | |
| Q1 2017 | +5.4% | +5.0% | +18.0% | |
| Q4 2016 | +1.9% | +6.6% | +9.9% | |
| Q3 2016 | +8.7% | +24.5% | +10.9% | |
| Q2 2016 | -4.2% | -5.0% | -11.9% | |
| Q1 2016 | +2.6% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | -2.4% | — | — | |
| Q2 2015 | +6.9% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -6.8% | — | — | |
| Q2 2014 | +4.7% | — | — | |
| Q1 2014 | -2.5% | — | — | |
| Q4 2013 | +5.4% | — | — | |
| Q3 2013 | +2.3% | — | — | |
| Q2 2013 | -6.6% | — | — | |
| Q1 2013 | +5.7% | — | — | |
| Q4 2012 | -3.2% | — | — | |
| Q3 2012 | -8.3% | — | — | |
| Q2 2012 | +11.7% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | -3.6% | — | — | |
| Q3 2011 | -3.5% | — | — | |
| Q2 2011 | +0.8% | — | — | |
| Q1 2011 | +1.3% | — | — | |
| Q4 2010 | -0.6% | — | — | |
| Q3 2010 | -3.4% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q1 2010 | +3.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro